Free tool
FAERS Monitor: Tazorac
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021184 or its brand name (Tazorac, Tazarotene). Reports on generic versions are filed under their own applications.
Reports
945
Serious
382
40% of reports
Hospitalization
164
Death reported
15
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective94
- off label use74
- pain52
- headache51
- erythema47
- pruritus44
- skin exfoliation42
- rash41
- psoriasis40
- diarrhoea36
- nausea34
- acne33
- pregnancy32
- dry skin31
- fatigue31
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 29 |
| 2006 | 12 |
| 2007 | 13 |
| 2008 | 17 |
| 2009 | 8 |
| 2010 | 43 |
| 2011 | 30 |
| 2012 | 75 |
| 2013 | 47 |
| 2014 | 24 |
| 2015 | 40 |
| 2016 | 88 |
| 2017 | 57 |
| 2018 | 68 |
| 2019 | 67 |
| 2020 | 37 |
| 2021 | 25 |
| 2022 | 40 |
| 2023 | 88 |
| 2024 | 46 |
| 2025 | 38 |
| 2026 | 42 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,214 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pregnancySignal | 32 | 35.6 | 25.3 | 1,042 |
| skin exfoliationSignal | 42 | 11.1 | 8.2 | 377 |
| acneSignal | 33 | 9.7 | 6.9 | 249 |
| psoriasisSignal | 40 | 6.8 | 5.0 | 194 |
| dry skinSignal | 31 | 5.2 | 3.7 | 101 |
| erythemaSignal | 47 | 5.1 | 3.9 | 152 |
| pruritusSignal | 44 | 2.5 | 1.9 | 41 |
| rashSignal | 41 | 2.1 | 1.6 | 23 |
| pain | 52 | 1.9 | 1.4 | 21 |
| off label use | 74 | 1.9 | 1.5 | 31 |
| headache | 51 | 1.8 | 1.4 | 18 |
| drug ineffective | 94 | 1.6 | 1.3 | 21 |
| diarrhoea | 36 | 1.2 | 0.9 | 2 |
| nausea | 34 | 1.0 | 0.7 | 0 |
| fatigue | 31 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.